Teva Pharmaceutical Industries said Friday it had accumulated 4.61 percent of local generic drugmaker Mylan, an amount that would allow the Israeli drug giant to get a hearing in Dutch court “should it become necessary.”

Teva, whose approximately $40 billion takeover offer for Netherlands-based Mylan was rebuffed in April, presumably would ask the court to nullify Mylan’s poison pill anti-takeover defense, arguing that it wasn’t in the best interest of shareholders.

Teva began buying shares after Mylan’s board rejected the takeover offer. Mylan officials have said they plan to keep the company independent, and are moving forward with a bid to buy over-the-counter drugmaker Perrigo even though Perrigo’s board has rejected it.

Analysts have speculated that Teva would soon sweeten its bid for Mylan in a tender offer, triggering Mylan’s poison pill, which Teva would then challenge in court.

Advertise with us

The maneuvering likely would come before a special Mylan shareholders meeting planned for late July or early August, analysts said, at which shareholders will be asked to approve a takeover of Perrigo.

Patricia Sabatini: psabatini@post-gazette.com; 412-263-3066.